JSH Guidelines for the Management of Hepatitis B Virus Infection.
about
Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendationsCurrent and future directions for treating hepatitis B virus infectionAdd-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir.IFN-CSP inhibiting hepatitis B virus in HepG2.2.15 cells involves JAK-STAT signal pathwayOutcomes of the implementation of the computer-assisted HBView system for the prevention of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis.Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs.Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody.Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era.Analysis of HBsAg using high-sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays.Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort.Survival in patients with Child-Pugh class C cirrhosis: Analysis of the liver transplant registry in Japan.Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α.Tacrolimus successfully used to control refractory eosinophilic granulomatosis with polyangiitis complicated by invasive aspergillosis and chronic hepatitis B.Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.Ulcerative colitis with hepatitis B virus infection treated successfully by granulocyte monocyte apheresis.Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies.A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.Evaluation of the highly sensitive chemiluminescent enzyme immunoassay "Lumipulse HBsAg-HQ" for hepatitis B virus screening.Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B.Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan.Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection.Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C.The combination of anti-HBc and anti-HBs levels is a useful predictor of the development of chemotherapy-induced reactivation in lymphoma patients with resolved HBV infection.Evidence-based clinical practice guidelines for inflammatory bowel disease.
P2860
Q26784247-07D8E982-52E4-4057-B41A-7ED60C58E286Q26851240-DF03D87C-1C35-45A6-B6D5-DB9E79018443Q33604145-B6F27A9D-4895-4B28-83EE-EAAB33154BEBQ35230043-E387FE4C-73FC-470C-822D-8C3D5ADFE415Q36508888-2A48E185-A3F7-4AF9-B96A-79A1DBBD125CQ38566383-756B76F2-57D6-4CE8-B296-1C441878D646Q39174722-D959A11D-74E3-40F2-B8F0-22487789D022Q39558394-68612BAB-1769-49C6-BF61-8E4643BA07E5Q39643993-6CDA9233-7FFE-41E4-88E4-8DE0B2D117D0Q40051443-33319225-A978-4D55-A242-72D55EA0B411Q40151821-16E02A56-E4E3-4514-9505-C14F90A0091DQ40166488-C339EA47-849E-4CB6-A354-E37F94732B40Q40171284-C62A22CE-2CAA-4E9F-B33A-FA3476E7379AQ40403002-8804DE50-A9D5-4467-B522-C3149C6026DAQ40557516-6CF2942A-3147-4A94-B8F1-2A5C10679B98Q40695032-16B6C24E-F1AF-4761-BD7E-5242810A9ECCQ40712186-5694E333-AACE-4A69-8E77-58AE8298D01EQ40791556-44A55EBB-52A5-400B-A11B-3D4055F837F0Q40810286-85A7F8F8-5963-461B-9886-26AAC29158CAQ41418657-A2D501F2-DC36-4E8D-9C1A-80B3C120C071Q41922981-CFB569AA-C480-44FA-90CD-1CE4630EED10Q42695116-325A90B0-6671-46AA-AB92-6B82359B08D6Q45324374-2CF6B545-B9EE-44CF-A574-75995065D0DBQ45325150-84E59C46-B5F0-4163-989A-A4D238254933Q45326295-14B3A7EE-E946-4EB7-A438-0F9B2D2E20FFQ45329330-4989E53F-4456-47BB-A3C5-8A098D662BFCQ47096774-FD3745AE-F555-4C0E-81CB-E9EF5F11A299Q50079201-ADA45C84-01D9-4739-B942-8E8F12B7869A
P2860
JSH Guidelines for the Management of Hepatitis B Virus Infection.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
JSH Guidelines for the Management of Hepatitis B Virus Infection.
@en
JSH Guidelines for the Management of Hepatitis B Virus Infection.
@nl
type
label
JSH Guidelines for the Management of Hepatitis B Virus Infection.
@en
JSH Guidelines for the Management of Hepatitis B Virus Infection.
@nl
prefLabel
JSH Guidelines for the Management of Hepatitis B Virus Infection.
@en
JSH Guidelines for the Management of Hepatitis B Virus Infection.
@nl
P2860
P356
P1433
P1476
JSH Guidelines for the Management of Hepatitis B Virus Infection.
@en
P2093
Drafting Committee for Hepatit ...... he Japan Society of Hepatology
P2860
P356
10.1111/HEPR.12269
P478
44 Suppl S1
P577
2014-01-01T00:00:00Z